Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Quoin Pharmaceuticals Ltd. publishes a filing, an earnings call transcript or a press release.

Get QNRX alerts

About Dr. Michael Myers

Dr. Michael Myers is recorded as Board Member at Quoin Pharmaceuticals Ltd. (QNRX) since October 26, 2023 and CEO at Quoin Pharmaceuticals Ltd. (QNRX). The newest filing on record that lists Dr. Michael Myers as CEO at Quoin Pharmaceuticals Ltd. (QNRX) is dated July 16, 2026. Quoin Pharmaceuticals Ltd. reported in an 8-K filed August 20, 2026 a re-election or new board role (director) for Dr. Michael Myers, on the board since at least 2023, effective August 20, 2026. Quoin Pharmaceuticals Ltd. reported in an 8-K filed December 10, 2024 that Dr. Michael Myers was appointed Director, effective December 5, 2024. Quoin Pharmaceuticals Ltd. reported in an 8-K filed November 1, 2023 that Dr. Michael Myers was appointed director, effective October 26, 2023. The proxy statement of Quoin Pharmaceuticals Ltd. reports total compensation of $1,507,345 for Dr. Michael Myers in fiscal 2025, including a base salary of $745,284. Disclosed compensation is on record for 4 fiscal years. Dr. Michael Myers has spoken on 5 earnings calls across 1 company, most recently for Quoin Pharmaceuticals Ltd. on March 14, 2024. Quoin Pharmaceuticals Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Quoin Pharmaceuticals Ltd. includes Sally Lawlor (CFO and Chief Accounting Officer), Denise Carter (COO and Board Member), Dr. Dennis H. Langer (Board Member) and 4 others.

“The shareholders elected the following directors to serve as a director of the Company until the Company's next annual general meeting of shareholders and until such director's successor is duly elected and qualified, or until such director's earlier resignation or retirement, based upon the following votes:”
Quoin Pharmaceuticals Ltd. Form 8-K, filed August 20, 2026 · Read the filing
“The shareholders elected the following directors to serve on Quoin's Board of Directors until Quoin's 2025 annual meeting of shareholders and until such director's successor is duly elected and qualified, or until such director's earlier resignation or retirement, based upon the following votes:”
Quoin Pharmaceuticals Ltd. Form 8-K, filed December 10, 2024 · Read the filing

Dr. Michael Myers on recent calls

“We are pleased to have the opportunity to report on Quoin's progress in the past quarter and throughout the year as a whole. 2023 was quite simply a truly transformational year for Quoin.”
CEO, Quoin Pharmaceuticals, Ltd. Q4 FY2023 Earnings Call ·
“During this past quarter, we continued to make significant progress across multiple fronts culminating in the release of additional positive clinical data for QRX003 from our ongoing open-label clinical trial in Netherton Syndrome after the quarter ended on October 24.”
CEO, Quoin Pharmaceuticals, Ltd. Q3 FY2023 Earnings Call ·
“On our last call, I reported on the very strong start Quoin has had to 2023. Today, I'm very pleased to announce that this momentum carried into and through the second quarter.”
CEO, Quoin Pharmaceuticals, Ltd. Q2 FY2023 Earnings Call ·
“I'm very pleased to report that Quoin has had a very strong start to 2023. Both of our Netherton Syndrome clinical trials, which are being conducted under an open IND, are fully up and running, actively recruiting and dosing patients.”
CEO, Quoin Pharmaceuticals, Ltd. Q1 FY2023 Earnings Call ·
“2022, which was Quoin's first full year as a publicly traded company, was a truly transformational one for us as we successfully delivered across all of our key operational targets.”
CEO, Quoin Pharmaceuticals, Ltd. Q4 FY2022 Earnings Call ·

Affiliation history

Company network

Leadership on record at Quoin Pharmaceuticals Ltd.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Quoin Pharmaceuticals Ltd. (QNRX) $745,284 $1,507,345
2024 Quoin Pharmaceuticals Ltd. (QNRX) $662,475 $1,406,801
2023 Quoin Pharmaceuticals Ltd. (QNRX) $602,250 $1,255,188
2022 Quoin Pharmaceuticals Ltd. (QNRX) $550,000 $1,966,799

Recent activity